Evidence map›Paper›PMID 25031664›Full record

ArticleCurrent therapeutic research, clinical and experimental2014

Effect of administration route on the pharmacokinetics of cobalamin in elderly patients: a randomized controlled trial.

Monique P H Tillemans, Eline M V J Donders, Sjoerd L Verweij, Ruud T M Van der Hoeven, Kees J Kalisvaart

Open access · goldAbstract read
In one paragraph

Article in Current therapeutic research, clinical and experimental, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Vitamin BBMJ (Clinical research ed.) · 2023
    Article
  5. Vitamin BMolecules (Basel, Switzerland) · 2022
    Review
  6. Review
  7. Intranasal treatment of vitamin BEuropean journal of pediatrics · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Monique P H TillemansStichting Apotheek der Haarlemse Ziekenhuizen, Haarlem, The Netherlands.
Eline M V J DondersDepartment of Geriatric Medicine, Kennemer Gasthuis, Haarlem, The Netherlands.
Sjoerd L VerweijStichting Apotheek der Haarlemse Ziekenhuizen, Haarlem, The Netherlands.
Ruud T M Van der HoevenStichting Apotheek der Haarlemse Ziekenhuizen, Haarlem, The Netherlands.
Kees J KalisvaartDepartment of Geriatric Medicine, Kennemer Gasthuis, Haarlem, The Netherlands.
Stichting Apotheek der Haarlemse Ziekenhuizen · NLSpaarne Gasthuis · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe gold standard for cobalamin deficiency treatment is administration of cobalamin by intramuscular injection. The injection is painful and inconvenient, particularly for elderly persons. Cobalamin might also be administered intranasally. Previous studies do not provide insight into the pharmacokinetics of intranasal cobalamin administration in comparison with cobalamin injection.

aimTo quantify the pharmacokinetics of intranasally and intramuscularly administered cobalamin to determine if intranasal administration might be an alternative for intramuscular administration.

methodsTen inpatients and outpatients of a geriatrics unit were recruited and randomly assigned to receive a single dose of 1000 μg cobalamin administered either by intranasal spray or intramuscular injection (5 per group). Inclusion criteria were written informed consent, age >65 years, and a cobalamin serum concentration <200 pmol/L. Total cobalamin serum concentrations were determined 10 times within 48 hours after administration. The differences in Cmax, Tmax, and AUC0-48 h per administration route were statistically compared using ANOVA.

resultsThe average Cmax was 1 nmol/L after intranasal and 38.5 nmol/L after intramuscular administration. The average Tmax for intranasal and intramuscular administration was 42 minutes versus 342 minutes, respectively, and the AUC0-48 h was 1.3 µmol/L/min versus 45.4 µmol/L/min, respectively. These values also differed significantly (P<0.05). The estimated bioavailability of the intranasal administration was 2%.

conclusionsThe pharmacokinetics of intranasal and intramuscular cobalamin administration in elderly, cobalamin-deficient patients differ significantly. However, the estimated 2% bioavailability of cobalamin after intranasal administration makes intranasal cobalamin administration a potentially interesting administration route for elderly patients. Netherlands Trial Registry identifier: NTR 3005.

Indexed as

cobalaminelderlyintramuscularintranasalpharmacokinetics

Identifiers

PMID25031664
PMCPMC3994916
OpenAlexW1993606089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.